Insider trades
Open-market buys and sales that US company officers, directors and 10% owners file, newest filing first.
| Trade type | ||||||||
|---|---|---|---|---|---|---|---|---|
Syndax PharmaceuticalsSNDX | Open-market sale10b5-1 plan | 06/11–06/12 | 06/12 | 65,515 sh2 trades | $18.07avg. | $1,183,642.9 | −51.8% | |
Syndax PharmaceuticalsSNDX | Open-market sale | 06/01 | 06/02 | 1,177 sh | $18.99 | $22,351.23 | −0.8% | |
Syndax PharmaceuticalsSNDX | Open-market sale | 06/01 | 06/02 | 6,847 sh | $18.99 | $130,024.53 | −1.4% | |
Syndax PharmaceuticalsSNDX | Open-market sale | 02/09 | 02/10 | 3,410 sh | $21.03 | $71,712.3 | −2.4% | |
Syndax PharmaceuticalsSNDX | Open-market sale | 02/09 | 02/10 | 17,159 sh | $21.03 | $360,853.77 | −3.4% | |
Syndax PharmaceuticalsSNDX | Open-market sale | 02/06 | 02/06 | 2,082 sh | $20.62 | $42,930.84 | −1.4% | |
Syndax PharmaceuticalsSNDX | Open-market sale | 02/06 | 02/06 | 7,412 sh | $20.62 | $152,835.44 | −1.4% | |
Syndax PharmaceuticalsSNDX | Open-market sale10b5-1 plan | 25/09/08 | 25/09/08 | 157,307 sh | $16.41 | $2,581,407.87 | −34.5% | |
Syndax PharmaceuticalsSNDX | Open-market sale10b5-1 plan | 25/08/14–25/08/18 | 25/08/18 | 57,600 sh3 trades | $15.19avg. | $874,944 | −23.1% | |
Syndax PharmaceuticalsSNDX | Open-market sale | 25/07/16 | 25/07/18 | 1,296 sh | $9.29 | $12,039.84 | −1.4% | |
Syndax PharmaceuticalsSNDX | Open-market sale | 25/07/16 | 25/07/18 | 7,534 sh | $9.29 | $69,990.86 | −2.5% | |
Keith KatkinDirector | Syndax PharmaceuticalsSNDX | Open-market buy | 25/05/19 | 25/05/19 | 10,000 sh | $9.11 | $91,100 | +11.1% |
Syndax PharmaceuticalsSNDX | Open-market buy | 25/05/19 | 25/05/19 | 3,000 sh | In footnote | No stated value | +3.3% | |
Martin H. Huber Jr.Director | Syndax PharmaceuticalsSNDX | Open-market buy | 25/05/19 | 25/05/19 | 5,000 sh | $8.99 | $44,950 | +6.8% |
Nicholas A.J. BotwoodHead of R&D, CMO | Syndax PharmaceuticalsSNDX | Open-market buy | 25/05/16 | 25/05/19 | 11,765 sh | $9.00 | $105,885 | +50.3% |
Syndax PharmaceuticalsSNDX | Open-market sale10b5-1 plan | 25/03/04 | 25/03/06 | 7,814 sh | $15.05 | $117,600.7 | −2.5% | |
Syndax PharmaceuticalsSNDX | Open-market sale | 25/02/10 | 25/02/12 | 3,777 sh | $15.50 | $58,543.5 | −4.0% | |
Syndax PharmaceuticalsSNDX | Open-market sale | 25/02/10 | 25/02/12 | 13,288 sh | $15.50 | $205,964 | −4.2% | |
Gallagher NeilPresident, Head of R&D | Syndax PharmaceuticalsSNDX | Open-market sale | 25/02/10 | 25/02/12 | 4,618 sh | $15.50 | $71,579 | −5.1% |
Syndax PharmaceuticalsSNDX | Open-market buy | 24/06/14 | 24/06/17 | 1,250 sh | $20.03 | $25,037.5 | +2.4% |